Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.54 |
| ▸ | KHK | P50053 | 2/20 | 0.53 |
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.45 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219269 | 0.84 | KHK (0.56) | MAPK14KHKHPGDSMAPK13 | |
| SCHEMBL2216064 | 0.83 | KHK (0.56) | MAPK14KHKHPGDSMAPK13RAF1 | |
| SCHEMBL2214287 | 0.81 | KHK (0.54) | MAPK14KHKHPGDSMAPK13RAF1 | |
| SCHEMBL2217584 | 0.78 | MAPK14 (0.64) | MAPK14MAPK13RAF1PDGFRAMAPKAPK2 | |
| SCHEMBL4219336 | 0.77 | HPGDS (0.55) | MAPK14KHKHPGDSMAPK13 | |
| SCHEMBL4222804 | 0.74 | HPGDS (0.51) | MAPK14KHKHPGDSMAPK13 | |
| SCHEMBL4220428 | 0.74 | HPGDS (0.51) | MAPK14KHKHPGDSMAPK13 | |
| SCHEMBL4217133 | 0.74 | MAPK13 (0.50) | MAPK14HPGDSMAPK13 | |
| SCHEMBL4225219 | 0.74 | HPGDS (0.53) | MAPK14HPGDSMAPK13 | |
| SCHEMBL2216634 | 0.73 | MAPK14 (0.49) | MAPK14KHKMAPK13MAPK11CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709046-B1 | P38 KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| US-20070161673-A1 | P38 kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161673-A1 | P38 kinase inhibitors | MAPK1, MAPK7, MAP3K1 | MAPK14 14/4885KHK 2805/4885HPGDS 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.